Newsroom
Sorted by: Latest
-
Simon Greenstone Panatier Earns Praise for Dallas, New York Offices
DALLAS--(BUSINESS WIRE)--Trial firm Simon Greenstone Panatier continues to earn accolades from the publishers of The Best Lawyers in America, earning placements in the 2027 edition of Best Law Firms for plaintiffs personal injury litigation and mass tort litigation/class actions representation. The firm earned Tier 1 placement, the highest possible, for both practice areas in Dallas-Fort Worth and was rated in the New York guide for plaintiffs personal injury litigation. “Our clients and peers...
-
Lost Money on MNTN, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 53.62% Stock Decline
LOS ANGELES--(BUSINESS WIRE)--MNTN, Inc. ("MNTN" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in MNTN, Inc. (NYSE: MNTN), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about MNTN, Inc. on November 4, 2026.If you lost money on MNTN, Inc. securities, share your...
-
GC AI and Docusign Partner to Turn Agreements into Legal Intelligence
SAN FRANCISCO--(BUSINESS WIRE)--GC AI, the legal intelligence platform built for in-house legal teams, has partnered with Docusign, the Intelligent Agreement Management company, to help legal and business teams find and analyze their contracts and deliver insights and answers faster. With this key integration, legal teams can analyze their entire Docusign contracts portfolio with GC AI’s Contract Intelligence feature, and support their business faster, with the information and context they need...
-
Kemper Announces Quarterly Dividend
CHICAGO--(BUSINESS WIRE)--Kemper Corporation (NYSE: KMPR) announced today that its Board of Directors has declared a quarterly dividend of $0.32 per share. The dividend is payable on December 2, 2026, to Kemper’s shareholders of record as of November 16, 2026. About Kemper The Kemper family of companies is one of the nation's leading specialized insurers. With approximately $12 billion in assets, Kemper is improving the world of insurance by providing affordable and easy-to-use personalized sol...
-
FDA dos EUA concede análise prioritária à combinação com BRUKINSA, da BeOne Medicines, para o tratamento de primeira linha do linfoma de células do manto
SAN CARLOS, Califórnia--(BUSINESS WIRE)--A BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa global do setor de oncologia, anunciou hoje que a Food and Drug Administration (FDA) dos EUA aceitou e concedeu "análise prioritária" (Priority Review) ao pedido suplementar de novo medicamento (sNDA, na sigla em inglês) para o BRUKINSA® (zanubrutinibe) em combinação com rituximabe, destinado ao tratamento de pacientes adultos com linfoma de células do manto (LCM) não tratado previam...
-
KBRA Assigns AAA Rating to State of Connecticut Special Tax Obligation Bonds, Transportation Infrastructure Purposes, 2026 Series B; Affirms Rating for Outstanding Bonds
NEW YORK--(BUSINESS WIRE)--KBRA assigns a long-term rating of AAA to the State of Connecticut Special Tax Obligation Bonds, Transportation Infrastructure Purposes, 2026 Series B. KBRA additionally affirms the long-term rating of AAA for the State's outstanding Special Tax Obligation Bonds, Transportation Infrastructure Purposes. The rating Outlook is Stable. Key Credit Considerations The rating actions reflect the following key credit considerations: Credit Positives Diverse pledged revenue sou...
-
Riassunto: L'FDA statunitense concede la Priority Review alla combinazione terapeutica con BRUKINSA di BeOne Medicines nel trattamento di prima linea del linfoma mantellare
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), un'azienda farmaceutica oncologica globale, oggi ha annunciato che la Food and Drug Administration (FDA) statunitense ha accettato e concesso la Priority Review (revisione prioritaria) alla sNDA (Supplemental New Drug Application, Domanda Supplementare di Nuovo Farmaco) per BRUKINSA® (zanubrutinib) in combinazione con rituximab per il trattamento di pazienti adulti affetti da linfoma mantellare (M...
-
La FDA de EE. UU. concede una revisión prioritaria a una combinación con BRUKINSA de BeOne Medicines para el tratamiento de primera línea del linfoma de células del manto
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), una compañía oncológica de alcance global, anunció hoy que la U.S. Food and Drug Administration (FDA) ha aceptado y concedido una revisión prioritaria a la solicitud complementaria de nuevo fármaco (sNDA) para BRUKINSA® (zanubrutinib) en combinación con rituximab para el tratamiento de pacientes adultos con linfoma de células del manto (LCM) no tratado previamente. La solicitud está respaldada por...
-
CareValidate Launches First Same-Day Prescription Delivery for Telehealth Brands, Starting with GLP-1 Treatments in Houston
ATLANTA--(BUSINESS WIRE)--CareValidate, the compliance and clinical infrastructure behind some of the fastest-growing telehealth brands in the country, is launching same-day prescription delivery in Houston. Telehealth businesses on the CareValidate platform can now offer eligible patients home delivery within hours instead of waiting days for traditional mail-order fulfillment. The launch starts with eligible compounded GLP-1 medications and the antinausea medication, ondansetron. CareValidate...
-
Bastion Fiduciary Acquires SJL Financial
ISLAMORADA, Fla.--(BUSINESS WIRE)--Bastion Fiduciary, a fee-only Registered Investment Advisor (RIA) acquires SJL Financial, fee-only financial planning firm founded by Sam Lewis....